Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹S.B. Bakırköy Doktor Sadi Konuk EAH, Göz Hastalıkları Kliniği, İstanbul, Uzm. Dr.
²S.B. İzmir Tepecik EAH, Göz Hastalıkları Kliniği, İzmir, Uzm. Dr.
³Ege Üniversitesi Tıp Fakültesi İstatistik Bölümü, İzmir, Uzm. Dr.
⁴İstanbul Üniversitesi İstanbul Tıp Fakültesi İç Hastalıkları A.D., İstanbul, Asist. Dr. Purpose: To evaluate the efficacy of photodynamic therapy in patients who had choroidal neovascularization due to agerelated macular degeneration (AMD).
Materials and Methods: Data on 30 eyes of 30 patients were evaluated. Sixteen patients were men and 14 were women. Mean age was 68.4±8.74 (47 to 81 years) years. Mean follow-up time was 15.7±3.28 months (10-22 months). The patients’ best corrected visual acuities were measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart number 2 and lesion types and the GLD of the lesions were measured by Topcon Image Net Fundus Camera. The indication for photodynamic therapy was based on the European Ophthalmology Society’s criteria published in 2001. The patients were invited to undergo control examinations 1 week and 3 months after the therapy and thereafter every 3 months. In each control examination the best corrected visual acuity was checked by ETDRS chart, fundus examinations were performed and fundus photographs were recorded by fundus camera, and FFA examinations was performed, especially in the first and second controls.
Results: After 2±1.44 therapies (ranging from 1 to 5) 22 patients (73.3%) could have been treated, but 8 patients (27.7%) had persistent CNVs. There was no significant difference in visual loss between the two groups but the loss in the successful group was 1.5 LogMAR standard lines less than that in the unsuccessful group.
Conclusion: Verteporfin with photodynamic therapy is an effective and safe procedure for exudative AMD therapy. Keywords : Age-related macular degeneration, verteporfin, photodynamic therapy